Keyphrases
Indoleamine 2,3-dioxygenase 1 (IDO1)
100%
Metastatic Melanoma
100%
In Cancer
100%
Immune Parameters
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Immune Escape
100%
Programmed Death-ligand 1 (PD-L1)
66%
HLA-A2
33%
Interleukin-2
33%
Clinical Benefit
33%
Epitope
33%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
33%
Vaccine Target
33%
Cancer Screening
33%
Immune Checkpoint
33%
Absolute Count
33%
Lymphocytes
33%
Patient Selection
33%
Clinical Response
33%
Melanoma Cells
33%
Phase 1 Clinical Trial
33%
Antibody Targeting
33%
CTLA-4 Inhibitors
33%
Temozolomide
33%
Conventional Chemotherapy
33%
Interferon-α (IFN-α)
33%
Therapeutic Vaccine
33%
Frequency Change
33%
Clinical Efficacy
33%
Tolerability
33%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Melanoma
100%
Malignant Neoplasm
100%
Indoleamine 2,3 Dioxygenase
100%
Immunotherapy
100%
Non Small Cell Lung Cancer
100%
Therapeutic Vaccine
33%
Sipuleucel T
33%
Interferon
33%
Lymphocyte Antigen
33%
Programmed Cell Death
33%
Temozolomide
33%
Prostate Cancer
33%
Interleukin 2
33%
Tolerability
33%
Epitope
33%
Chemotherapy
33%
Immunology and Microbiology
Sipuleucel-T
25%
Cytotoxic T Lymphocyte Antigen 4 Antibody
25%
Programmed Cell Death 1
25%
Immune Checkpoint Blockade
25%